# Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

> **NCT05564117** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 307 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo semaglutide

## Key facts

- **NCT ID:** NCT05564117
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-11
- **Primary completion:** 2024-04-18
- **Final completion:** 2024-05-07
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564117, "Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05564117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*